Active comparators are often included in phase 2 studies as a positive contrd to assess assay sensitivity, but inclusion of a positive contrd does not necessarily improve decision making. Examples show that positive contrds are more useful in assessing assay sensitivity as the probability the test drug is efective decreases and as power for the contrast of the positive contrd versus placebo increases. These results suggest that a positive control should be powered at a minimum of 80% and preferably at 90%.
Active comparators are often included in phase 2 studies as a positive contrd to assess assay sensitivity, but inclusion of a positive contrd does not necessarily improve decision making. Examples show that positive contrds are more useful in assessing assay sensitivity as the probability the test drug is efective decreases and as power for the contrast of the positive contrd versus placebo increases. These results suggest that a positive control should be powered at a minimum of 80% and preferably at 90%.
Analogously, a positive contrd can be used in an estimation framework to assess whether the study performed as expected, thereby indicating whether or not the test dmg was assessed under the anticipated conditions. In so doing, the sample would need to be suficiently large to ensure reliable estimation. The key point again is that results of the positive contrd must be reliable if they are to be useful, and adding a small sample of patients in a positive contrd arm can do more harm than good. It is also important to recognize that including a positive contrd only allows assessment, but not improvement, of assay sensitivity. Actual clinical trial data are used to suggest that two smaller two-arm studies of test drug and placebo instead of one larger study that also includes a positive contrd may improve assay sensitivity with little to no increase in the total sample size.
I N T R O D U C T I O N
At present, only about 9% of central nervous system (CNS) drugs that enter phase 1 testing survive to launch (1) . Approximately 50% of the failures are due to not demonstrating efficacy in phase 2, which is a 15% increase in failure rate over the previous decade (1). Meanwhile, the failure rate of CNS drugs in phase 3 is about 50% ( 2 ) , with problems in drug-placebo discrimination and increased placebo response rising at an alarming rate (3). These findings suggest that high rates of false negative and false positive results in phase 2 are a major obstacle in CNS drug development. In fact, improving proof-of-concept (PoC) clinical trials, which are frequently in phase 2, has been cited as the most important factor required for reducing the attrition rate in drug development Active comparators may be included in addition to a test drug and placebo in a clinical trial as a positive control to assess assay sensitivity, that is, to determine whether the study provided a valid test of the experimental drug (4). In-( 2 ) . tuitively, inclusion of a positive control in addition to placebo should help foster better decisions from a PoC trial. However, most of the literature on this topic is in reference to including placebo in addition to an active drug to establish equivalence of a test drug and a standard of care (4-12). The merits of a positive control to assess assay sensitivity have not been explored extensively in the literature for CNS drugs in general and psychiatric drugs in particular.
Hence, even though intuition suggests a positive control can foster better interpretations of the experimental drug, empirical data are lacking. Therefore, the objective of this research was to evaluate the usefulness of positive controls as an aid to decision making in phase 2 clinical trials. This objective is approached through the use of numerical analysis of hypothetical examples and examination of actual clinical trial data.
M E T H O D S
Describing the results of a study only in a hypothesis-testing framework (Was the difference statistically significant or not?) ignores potentially important distinctions. For example, consider three studies where the criterion for success was based on a statistically significant difference between test drug and placebo on the primary analysis based on an alpha (P value) cutoff of 0.05. If the P values for these three studies were 0.049, 0.051, and 0.999, based solely on statistical significance, study 1 looks very different from studies 2 and 3, whereas studies 2 and 3 look similar, In reality, studies 1 and 2 were similar. It just so happens that the P values fell on either side of the arbitrary cutoff of 0.05, and although neither studies 2 nor 3 were significant, in study 2 the difference barely missed significance whereas in study 3 the drug was almost certainly not superior to placebo.
Although summarizing results of a study merely as significant or not has obvious limitations, considering results in this black-andwhite framework is a useful starting point for understanding the role of positive controls when assessing assay sensitivity.
As will become clear in subsequent sections, the utility of using a positive control depends in part on whether or not the test drug is effective. Therefore, the use of positive controls to assess sensitivity is first addressed separately for cases where the test drug is in truth effective and when it is not effective. This distinction is useful to first fix ideas, but also results in hypothetical assessments, because efficacy of the test drug is typically not known at the start of phase 2. This difficulty is resolved in a subsequent section by moving from the black-and-white framework of effective or not effective to a subjective probability of efficacy framework. In addition, given the limitations of the hypothesis-testing framework, a subsequent section considers positive controls in an estimation framework.
The probabilities of various outcomes of trials including positive controls were evaluated using an analytic approach. Parameters were input to establish joint distributions that describe the results from contrasting a test drug and a positive control versus placebo. Inputs were varied to mimic several scenarios. For each scenario considered, the distribution was derived assuming a normally distributed endpoint with equal variance and equal sample size in each treatment arm. The mean effects of the test drug and positive control versus placebo were individually varied to yield the desired power by arm for a one-sided univariate test at an alpha of 0.05 without correcting for multiplicity. The resulting bivariate cumulative distribution function was used to compute the probabilities that a study finds both arms to be significant, only test drug significant, only positive control significant, or neither arm significant. All probabilities were computed using the probbnrm function in SAS 9.1 (code available upon request).
R E S U L T S

SCENARIOS WHERE THE TEST DRUG
IS EFFECTIVE
Tables summarize the probabilities of various outcomes when a test drug and a positive control are simultaneously compared with placebo in a study. Results are described in terms of success and failure, based on presence or absence of a statistically significant difference from placebo. Understanding these probabilities is the first step in developing a framework for quantitatively evaluating the utility of a positive control in phase 2 studies. Table 1 depicts a scenario where the test drug is effective, with the test drug and the positive control (correctly) powered at 80%. In this scenario, the correct result would be for both drugs to yield a significant difference from placebo. However, simply due to chance alone, each drug is expected to be nonsignificant in 20% of the trials. Hence, assuming independence of outcomes, an assumption explored momentarily, 64% (.80 30) of the trials are expected to yield a significant difference for both the test drug and the positive control. Therefore, at least one "wrong" result is expected in 36% (100% -64%) of the trials. More specifically, in 16% (.8 .2) of the trials only the test drug is expected to be significant. In another 16% (.2 * .8) only the positive control is expect-
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ed to be significant, and in 4% (.2 .2) neither is expected to be significant.
When the test drug is effective, separation from placebo by definition demonstrates assay sensitivity. Hence, in the 80% of the trials where the correct result of test drug separating from placebo is obtained, decision making is neither hindered nor helped by the wrong or correct result for the positive control. In the 16% of the trials where the wrong result is obtained for the test drug but the positive control separates, the presence of the positive control reinforces the false negative result. This is because it is logical to believe that the test drug should have separated if it were effective, since the study was sensitive to the effects of the positive control, In such cases, development would probably be stopped and the result would never be discovered as a false negative. In the remaining 4% of trials where neither arm is significant, the positive control helps inform us that the result for the test drug is a false negative, potentially leading to another study to further evaluate the drug. Table 2 is the same as Table 1 except that now each drug is powered at 50% rather than 80%, mimicking scenarios such as depression where effective drugs separate from placebo only about half the time regardless of sample sizes (U); similar problems in drug-placebo discrimination may be evolving in schizophrenia (3). Alternatively, such a scenario may arise in disease states where assay sensitivity is not a problem, but fewer patients are randomized to the positive control than to the test drug.
The correct result would again be for both drugs to yield a significant difference from placebo. However, as a consequence of lower power, only 25% of the trials are expected to yield a significant difference for both drugs. Therefore, at least one "wrong" result is expected in 75% of the trials. More specifically, in 25% of the trials only the test drug is expected to be significant; in 25% only the positive control is expected to be significant; and in 25% both are expected to be insignificant.
As before, in the 50% of trials where the correct result is obtained for the test drug, deci- the correlation between results for the treatment arms, assuming 80% power, the percentage of concordant results is greater than the expected frequencies assuming independence. Specifically, concordant results are expected in approximately 77.4% of the outcomes, whereas with independence, it is 68%. The increase in concordance from nonindependence reduced the frequency of trials where inclusion of a positive control reinforced a false negative result, but more than doubled the rate of socalled failed trials where neither the experimental nor positive control separated from placebo. Table 3 depicts a scenario where the test drug is not effective (test drug equal to placebo), with the test drug tested using a one-tailed test at alpha = 0.05, and the positive control (correctly) powered at 80%. In this scenario, the correct result would be for the positive control to yield a significant difference and for the test drug to be not significant. However, due to chance alone, the test drug is expected to be significant in 5% of the trials (with alpha = 0.05 the false positive rate is 5%) and the positive control is expected to be not significant in 20% of the trials. Hence, assuming independence of outcomes, a n assumption explored momentarily, Therefore. at least one "wrong" result is obtained in 24% of the trials. When the wrong result is obtained for the test drug, in 5% of the trials. presence of the positive control does not help identify the result as a false positive. In the 19% of the trials where neither drug separates. the presence of the positive control suggests that the trial failed and therefore did not adequately evaluate the test drug. In the 76% of trials where the correct result is obtained. the positive control reinforces the belief that the test drug is ineffective. Table 3 except the positive control is powered at 50% rather than 80%, as might be t h e case when randomizing fewer patients to the positive control than to the test drug, or in disease states where known active compounds frequently fail, even with large sample sizes. Again, the correct result would be for the positive control to yield a significant difference and for the test drug to be nonsignificant. However, due to chance alone. the test drug is again expected to be significant in 5% of the trials, but the positive control is expected to be not significant in 50% of the trials. Hence, assuming independence of outcomes, 2.5% of the trials are expected to yield a significant difference for both drugs, and the test drug alone is expected to be significant in 2.5% of trials. The correct result of the test drug being nonsignificant with the positive control significant is expected in 47.5% of the trials. In 47.5% of the trials, neither drug is expected to be significant.
SCENARIOS WHERE THE TEST DRUG IS NOT EFFECTIVE
Therefore, at least one "wrong" result is expected in 52.5% of the trials. When t h e wrong result is obtained for the test drug (5% of the trials), presence of the positive control does not help identify the result as a false positive. In the 47.5% of the trials where neither drug sepa-Positive controls i n Phase 2 Trials B I O S T A T l S T l C S 435 rates, the presence of the positive control suggests the trial was failed and thereby failed to adequately evaluate the test drug. In the 47.5% of trials where the correct result was obtained, the presence of the positive control correctly reinforces the belief that the test drug is ineffect ive.
Accounting for the correlation between treatment arms had little impact on results in these scenarios where the true effects of the test drug and positive control were not concordant. Cell frequencies were altered by less than 2%. Therefore, results from Table 3 and Table 4 reasonably reflect what to expect when a test drug is not effective.
PROBABILITY-OF-SUCCESS FRAMEWORK
The summaries in the previous sections assuming that a drug is or is not effective are intuitively useful, but of limited practical value. If it is known whether or not the test drug is effective, there is no need to do the study. Therefore, it is useful to consider positive controls from a perspective based on the subjective probabilities of the test drug being effective.
To incorporate this perspective, the consequences of the various outcomes on drug development decisions and the utility of the positive control in making those decisions need to be considered. Assume that, if the test drug is significant, development will proceed to phase 3; if the test drug is not significant and the positive control is significant, then development is stopped: if neither the test drug nor the positive control is significant, then the PoC trial is repeated.
To classify positive control outcomes as neutral, helpful, or harmful, consider first each quadrant of Table 1 and then Table 3 Table 5 with additional information about the decision, utility of the positive control, and action taken. The probabilities that the positive control has a helpful, neutral, or harmful effect are 0.087,0.800, and O.ll3, respectively. Thus, in these scenarios where the test drug is effective, the positive control is seldom beneficial, and just as often harmful, but always increases the cost and duration of the studies.
The results from Table 3 (modified to account for correlation) where the test drug is not effective are repeated in Table 6 with additional information about the decision, utility of the positive control, and action taken. When the test drug separates from placebo, the positive control reinforces the false positive result (left and right quadrants of the top row in Table 3 ). When the test drug does not separate from placebo and the positive control does (left quadrant of the lower row in Table 3 ), the positive control helps because it provides more confidence that Table 3 ), the positive control is harmful because it erroneously suggests that the study was not capable of finding a difference. The probabilities that the positive control has a helpful or harmful effect are 0.751 and 0.249, respectively, with the positive control never having a neutral effect, but again always adding to the cost and duration of the studies. It is further useful to consider positive controls over the development of many compounds, some of which will be proven as effective therapies and many of which will not.
To incorporate this perspective, two scenarios are considered: one where 50% of the drugs entering phase 2 are in fact effective and another where 33.3% are effective. While these choices are arbitrary, they are intended to be illustrative of scenarios with higher than usual and usual optimism for success, respectively. Table 7 summarizes the utility of positive controls across a portfolio of compounds when the positive controls are powered at 80%. These results are based on the probabilities as shown in Tables 5 and 6. Table 8 provides the same information when the power of the positive control is increased to 90%, and, if effective, the test drug remains powered at 80%.
When the positive control is powered at 80%, with 50% of the test drugs being effective, the frequency of the positive control having a beneficial, neutral, or harmful effect across the portfolio is 42%, 40%, and 18%. When powered at 80% with 33.3% of the test drugs being effective, the corresponding percentages are 533,27%, and 20%.
When the positive control is powered at 90%, with 50% of the test drugs being effective, the I I frequencies of a positive control having a beneficial, neutral, or harmful effect are 45%, 40%, and 15%, respectively. When powered at 90% with 33.3% of the test drugs being effective, the corresponding percentages are 58%, 27%, and 15%.
ESTIMATION FRAMEWORK
Rather than basing assay sensitivity on a hypothesis test to ascertain whether the known effective positive control separated from placebo, an estimation framework can be used. For example, instead of looking at statistical significance, the point estimate and associated confidence intervals for the contrast of the positive control versus placebo can be compared with historical data to see whether the positive control results are in line with historical results. Although both the hypothesis testing and estimation frameworks rely on the same data, the estimation framework provides a more granular look at the results, and therefore has potential advantages. Details on estimation versus hypothesis testing are beyond the scope of this article. Instead, we focus on what questions need to be addressed to understand the utility of a positive control to assess assay sensitivity because both frameworks lead to the same fundamental point. Namely, if results from the positive control are to be beneficial in assisting decision making, they must be reliable enough to be trusted.
In the hypothesis-testing framework, reliability can be addressed via power, whereas in the estimation framework reliability can be addressed via width of the confidence interval for the positive control contrast with placebo.
A REAL-DATA E X A M P L E
Prior to approval of duloxetine for major depressive disorder, ll clinical trials were conducted that included 15 treatment arms of duloxetine tested versus placebo. In 7 of those studies, which included 11 duloxetine treatment arms, a positive control (SSRI) was also included. Among these 7 SSRI arms, 5 had equal randomization to duloxetine and 2 had half as many patients as duloxetine. These studies have been published individually (14-21) and in summaries (22,23), with additional details being available at ClinicalTrials.gov (24). If each duloxetine arm is viewed as a standalone PoC trial, the value of the positive control in regard to assessing assay sensitivity can be evaluated. Results from the 11 duloxetine arms are cross-tabulated with results from the SSRI arms in Table 9 .
Duloxetine separated from placebo in 8 of 11 (73%) contrasts. SSRI separated from placebo in 2 of 7 (28%) contrasts. Since four studies had multiple duloxetine arms, the 7 SSRI contrasts are paired with 11 duloxetine contrasts, thereby double counting some SSRI contrasts.
Given that all the drugs tested in these trials were FDA approved for treatment of major depressive disorder, the correct result would be for both duloxetine and SSRI to separate from MaUinckrodt et al.
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placebo. The correct result was observed in 2 of 11 contrasts. In the 8 contrasts where duloxetine separated from placebo (top left and top right quadrant of Table 9 ), including the SSRI had a neutral effect. In the 3 contrasts where duloxetine did not separate, the SSRI helped in 1 instance because neither duloxetine nor SSRI separated from placebo (lower right quadrant of Table 9 ), suggesting a failed study: however, in two contrasts SSRI erroneously supported the false negative result for duloxetine (lower left quadrant of Table 9 ). Effect sizes from the primary analysis of the HAMD17 total score and whether or not that difference was statistically significant are summarized by dose in Table 10 . Interestingly, duloxetine separated from placebo in 4 of 4 (100%) of the studies that did not include a positive control. The average effect size on the HAMD17 from two-arm studies was 0.53 compared with 0.39 for studies that included a positive control. Previous research has shown that subscales of the HAMD may improve signal detection compared with the total score (25-28). The average effect size on the Maier subscale (29) of the HAMD from two-arm studies was 0.63 compared with 0.45 for studies that included a positive control.
The larger effect sizes from the two-arm studies are especially noteworthy in that the average duloxetine daily dose in those studies was just over 60 mg, whereas in the studies with a positive control the average daily dose was approximately 80 mg.
It is also noteworthy that 12 of the 15 duloxetine treatment arms arose from having two identical studies run via the same protocol. Each study was independently and adequately powered, but designed to be pooled to increase precision. At least one positive result was obtained at each dose level in each pair of studies.
D I S C U S S I O N
While it may be tempting to assume including a positive control is useful given that it allows assessment of assay sensitivity, the example scenarios and real-data examples included in this research suggest the matter needs to be evaluated on a case-by-case basis and is not clear cut.
Careful consideration reveals the following conundrum. If assay sensitivity is low, it is difficult to trust the results of the study, especially negative results for a test drug. But including a positive control may not improve decision making since the results from this contrast with placebo are also unreliable. On the other hand, if assay sensitivity is good, results of the study can be trusted and we can trust the results from the test drug, thereby negating the need for a positive control.
More specifically, in scenarios where an effective test drug separates from placebo, the inclusion of a positive control is not useful because separation of the test drug establishes assay sensitivity. When the effective test drug fails to separate, the frequency of the positive control reinforcing a false negative result versus correctly identifying a failed study is proportional to the power of the active arm. In other words, if the test drug is effective, the probability of good decision making stemming from use of a positive control is inversely related to the power of the positive control.
In scenarios where the test drug is in truth not effective but is nevertheless found to be significant, inclusion of a positive control does not protect against this false positive result, but rather reinforces it. When the ineffective test drug fails to separate, the frequency that the positive control reinforces this true negative result versus incorrectly identifying a failed study is proportional to the power of the active arm. In other words, if the test drug is not effective, the probability of a correct decision stemming from use of a positive control is directly related to the power of the positive control.
Positive Controls in
Taking a probability perspective on the use of positive controls to assess assay sensitivity reveals that the positive control should be highly powered, perhaps 80-90%, to be useful. In other words, results of the positive control must be reliable if they are to be useful. In addition, the positive control will be more useful when the probability that the test drug is effective is lowe r.
It is important to realize that positive controls assess assay sensitivity; they do not improve it. In fact, a recent meta-analysis demonstrated that the most important factors influencing drug-placebo discrimination for antidepressants was the percentage of patients randomized to placebo (30). As the percentage of patients randomized to placebo decreased, for example when adding a positive control, the drug-placebo difference decreased. Similar findings have been reported by other researchers (U.31.32) and are consistent with the duloxetine example presented here.
Examination of the summary basis approval data set of antidepressant clinical trials showed that an active comparator separated from placebo in only about 60% of the trials (31), well below the 80-90% required to enhance decision making. Therefore, rather than assessing assay sensitivity, means to improve assay sensitivity should be considered.
For example, two smaller two-arm studies of test drug and placebo instead of one larger study that also includes a positive control may improve assay sensitivity with little to no increase in the total sample size.
C O N C L U S I O N
Positive controls are more useful in assessing assay sensitivity as the probability the test drug is effective decreases and as power for the contrast of the positive control versus placebo increases. The positive control should be powered at a minimum of 80%, and preferably at 90%. Including a positive control only allows assess-
